Skip to main navigation Skip to search Skip to main content

Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls

  • Kathryn L. Terry
  • , Stalo Karageorgi
  • , Yurii B. Shvetsov
  • , Melissa A. Merritt
  • , Galina Lurie
  • , Pamela J. Thompson
  • , Michael E. Carney
  • , Rachel Palmieri Weber
  • , Lucy Akushevich
  • , Wei Hsuan Lo-Ciganic
  • , Kara Cushing-Haugen
  • , Weiva Sieh
  • , Kirsten Moysich
  • , Jennifer A. Doherty
  • , Christina M. Nagle
  • , Andrew Berchuck
  • , Celeste L. Pearce
  • , Malcolm Pike
  • , Roberta B. Ness
  • , Penelope M. Webb
  • Mary Anne Rossing, Joellen Schildkraut, Harvey Risch, Marc T. Goodman
  • Brigham and Women’s Hospital
  • Harvard University
  • University of Hawai'i at Mānoa
  • Cedars-Sinai Medical Center
  • Duke University
  • University of Pittsburgh
  • Fred Hutchinson Cancer Research Center
  • Stanford University
  • Dartmouth College
  • Queensland Institute of Medical Research
  • University of Southern California
  • Memorial Sloan-Kettering Cancer Center
  • University of Texas Health Science Center at Houston
  • Yale University

Research output: Contribution to journalArticlepeer-review

95 Scopus citations

Abstract

Genital powder use has been associated with risk of epithelial ovarian cancer in some, but not all, epidemiologic investigations, possibly reflecting the carcinogenic effects of talc particles found in most of these products. Whether risk increases with number of genital powder applications and for all histologic types of ovarian cancer also remains uncertain. Therefore, we estimated the association between self-reported genital powder use and epithelial ovarian cancer risk in eight population-based case-control studies. Individual data from each study were collected and harmonized. Lifetime number of genital powder applications was estimated from duration and frequency of use. Pooled ORs were calculated using conditional logistic regression matched on study and age and adjusted for potential confounders. Subtype-specific risks were estimated according to tumor behavior and histology. 8,525 cases and 9,859 controls were included in the analyses. Genital powder use was associated with a modest increased risk of epithelial ovarian cancer [OR, 1.24; 95% confidence interval (CI), 1.15-1.33] relative to women who never used powder. Risk was elevated for invasive serous (OR, 1.20; 95% CI, 1.09-1.32), endometrioid (OR, 1.22; 95% CI, 1.04-1.43), and clear cell (OR, 1.24; 95% CI, 1.01-1.52) tumors, and for borderline serous tumors (OR, 1.46; 95% CI, 1.24-1.72). Among genital powder users, we observed no significant trend (P = 0.17) in risk with increasing number of lifetime applications (assessed in quartiles). We noted no increase in risk among women who only reported nongenital powder use. In summary, genital powder use is a modifiable exposure associated with small-to-moderate increases in risk of most histologic subtypes of epithelial ovarian cancer.

Original languageEnglish
Pages (from-to)811-821
Number of pages11
JournalCancer Prevention Research
Volume6
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Dive into the research topics of 'Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls'. Together they form a unique fingerprint.

Cite this